Swedish Orphan Bio Spon (NASDAQ:SWTUY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
Shares of Swedish Orphan Bio Spon (NASDAQ SWTUY) traded down 0.51% during midday trading on Wednesday, reaching $15.72. The stock’s 50 day moving average price is $15.72 and its 200 day moving average price is $15.21. The company has a market cap of $4.23 billion and a PE ratio of 53.11. Swedish Orphan Bio Spon has a 52-week low of $10.25 and a 52-week high of $16.49.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/09/20/zacks-investment-research-downgrades-swedish-orphan-bio-spon-swtuy-to-hold.html.
Receive News & Ratings for Swedish Orphan Bio Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Bio Spon and related companies with MarketBeat.com's FREE daily email newsletter.